CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

Similar documents
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

日本化学療法学会雑誌第61巻第6号

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

日本化学療法学会雑誌第64巻第4号

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.


Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

CHEMOTHERAPY

Fig.1 Chemical structure of BAY o 9867

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum



CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str


coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

CHEMO THE RAPY OCT. 1994

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

CHEMOTHERAPY

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

Fig. 1 Chemical structure of DL-8280

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

R06_01

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis

1272 CHEMOTHERAPY MAR. 1975


Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

988 CHEMOTHERAPY NOV. 1971

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study


VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY


CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY JUNE 1986

日本化学療法学会雑誌第58巻第4号



VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia



Fig. 1 Chemical structure of KW-1070

PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin

Table1MIC of BAY o 9867 against standard strains

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

VOL. 34 S-2 CHEMOTH8RAPY 913


CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

VOL. 43 NO. 4

THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

VOL.42 S-1


- 1 -

Table 1. Antimicrobial drugs using for MIC

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur

VOL.27 S-5 CHEMOTHERAPY Table 1 Clinical evaluations of cefamandole on UTI (1) Benign prostatic hypertrophy (2) Transurethral resection of bladder tum


Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

MIC MIC...



untitled

03-b-„FŒ{›xŒ¾-4.02

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile


HPM_442_F_TgCHG_1128


2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.

ヒビスコール液A カタログ

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

Fig. 1 Chemical structure of norfioxacin (AM-715)

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG


2.7 臨床概要

日本化学療法学会雑誌第59巻第5号


Acecide_ProductsInformation2010PDF.indd


04-c-„FŒ{›xŒ¾-4.01

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC


Transcription:

aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39, Pseudomonas aeruginosa 50,c/ernl methicillin-resistant influenzae, Branhamella catarrhalis, K. pneumoniae, P. aeruginosa, Xanthomonas malto- StaPhylococcus aureus (MRSA), Enterococcus faecalis Serratia marcescens, Pseudomonas aer- Serratia marcescens Proteus mirabilis 8 Staphylococcus aureus E. faecalis Escherichia coli Klebsiella Pneumoniae Enterobacter cloacae Enterobacter aerogenes 8 Proteus vulgaris Citrobacter freundii 27

VOL39 S-3

SEPT.1991 Table 1. Antimicrobial activity of panipenem and other agents against clinical isolates

VOL.39 S-3

Table 3. Laboratory findings of cases treated with panipenem/betamipron

VOL. 39 S-3 pneumoniae, P. aeruginosa, X. maltophilia, B. catarrhalis, H. influenzae, K.

SEPT. 1991 FUNDAMENTAL AND CLINICAL STUDIES ON PANIPENEM/BETAMIPRON Yoshiro Sawae, Kaoru Okada, Toshiyuki Ishimaru, Kouji Takagi, Nobuyuki Shimono, Hiroyasu Misumi, Kazuhiko Aoyagi, and Yoshiyuki Niho First Department of Internal Medicine, Faculty of Medicine, Kyushu University and School of Health Sciences 3-1-1, Maidashi, Higashi-ku, Fukuoka 812, Japan Fundamental and clinical studies were conducted using panipenem/betamipron (PAPM/BP) which is an injectable combined drug of newly developed carbapenem antibiotic, panipenem (PAPM) and N-benzoyl-ƒÀ-alanine (betamipron (BP)) at a ratio of 1: 1, and the results were obtained as follows. 1) The MICs of PAPM and the control drugs such as imipenem (WM), piperacillin (PIPC), cefoperazone (CPZ) and ceftazidime (CAZ) against the clinical isolates were determined in accordance with the Standard Method established by Japan Society of Chemotherapy. The MIC80s of PAPM against Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens, Proteus mirabilis, Proteus vulgaris, Citrobacter freundii and Pseudomonas aeruginosa were 0.10, 3.13, 0.20, 0.78, 0.78, 0.78, 3.13, 1.56, 0.39 and 50/2g/ml, respectively, and the antibacterial activity of PAPM was as potent as that of IPM. In particular, the antibacterial activity of PAPM against Gram-positive cocci was far more potent than that of PIPC, CPZ and CAZ. The antibacterial activity of PAPM against P. aeruginosa was as potent as that of PIPC, CPZ and CAZ, but PAPM showed more potent antibacterial activity than the control drugs against most other Gram-negative bacilli except for Proteus spp. 2) PAPM/BP was used in the treatment of 7 patients (3 patients with pneumonia, 1 with chronic bronchitis, 1 with sepsis and 2 with cystitis). Their age ranged from 30 years to 74 years and there were 2 males and 5 females. All of these patients had one or more underlying diseases which are prone to cause infectibility. PAPM/BP was given in the daily dosage of 1.0g/1.0g `2.0g/2.0g for 3 `23 days, and the clinical response was excellent in 1 case, good in 5 and unknown in 1. The identified causative bacteria included Haemophilus influenzae, Branhamella catarrhalis, P. aeruginosa, Xanthomonas maltophilia and K. pneumoniae and most of these causative bacteria became negative. But in 2 cases, the causative bacteria were replaced. Neither side effect nor abnormal laboratory test value were observed.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック